Skip to Main Content

++

INTRODUCTION

++

lisdexamfetamine (lis-deks-am-fet-a-meen)

Vyvanse

Classification

Therapeutic: central nervous system stimulants

Pharmacologic: sympathomimetics

Schedule II

++
Indications
++

Management of attention deficit hyperactivity disorder (ADHD) (in adults and children).

++
Action
++

Blocks reuptake and increases release of norepinephrine and dopamine resulting in increased levels in extraneuronal space. Therapeutic Effects: Improved attention span in ADHD.

++
Adverse Reactions/Side Effects
++

CNS: behavioral disturbances, dizziness, hallucinations, insomnia, irritability, mania, psychomotor hyperactivity, thought disorder, tics. EENT: blurred vision, poor accommodation. GI: abdominal pain, ↓ appetite, dry mouth, nausea, vomiting. Derm: rash. Metab: ↓ weight. Misc: long-term growth suppression.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor attentiveness and behavior in patients with ADHD. Report any changes in attention and hyperactivity, and document whether this drug appears to be producing the desired effects.

  • Be alert for signs of excessive CNS stimulation, including increased activity, hallucinations, mania, irritability, tics, disordered thoughts, or behavioral disturbances. Report these signs to the physician.

  • Assess dizziness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician, and caution the patient and family/caregivers to guard against falls and trauma.

  • Assess growth rate in children receiving chronic therapy; report delayed or stunted growth to the physician.

  • Periodically assess body weight and other anthropometric measures (body mass index, body composition). Report a rapid or unexplained weight loss or decreased body fat.

++
Patient/Client-Related Instruction
++

  • Instruct patient and family/caregivers to report other troublesome side effects, including severe or prolonged sleep loss, vision disturbances, skin rash, or GI problems (nausea, vomiting, decreased appetite, abdominal pain, dry mouth).

++
Pharmacokinetics
++

Absorption: Rapidly absorbed and converted to dextroamphetamine, the active drug.

++

Distribution: Unknown.

++

Metabolism and Excretion: 42% excreted in urine as amphetamine.

++

Half-life: <1 hr for lisdexamfetamine.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION
PO rapid 1 hr 24 hr

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity to lisdexamfetamine or other sympathomimetic amines; Advanced arteriosclerosis; Symptomatic cardiovascular disease, including known structural cardiac abnormalities (may increase the risk of sudden death); Moderate-to-severe hypertension; Glaucoma; Agitation; OB: Lactation; History of substance abuse; During or within 14 days of monoamine oxidase inhibitor therapy.

++

Use Cautiously in: History of preexisting psychosis, bipolar disorder, aggression, tics, Tourette's syndrome or seizures (may exacerbate condition); OB: Use in pregnancy only if maternal benefit outweighs fetal risk.

++
Interactions
++

Drug-Drug: Serious adverse reactions, including hyperpyrexia and hypertension, may occur with monamine oxidase inhibitors; avoid use within 14 days. Concurrent use of other sympathomimetic amines may result in additive effects and ↑ risk of adverse ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.